MORRISTOWN, N.J. (AP) -- Watson Pharmaceuticals Inc. said Friday it resumed shipments of its intravenous iron replacement INFeD, about three months after it recalled the product.
Watson issued a recall of INFed in April due to manufacturing problems with the raw materials of the drug. Watson said the drug is returning to the market sooner than expected, as the company had suggested it might not be able to ship any more INFeD for the rest of 2009.
INFeD, or iron dextran injection, is a treatment for iron deficiency anemia. Watson began selling the drug in 1992. The company said the drug was out of stock, but it expects to reach normal supply levels soon.
The drug is sold by Watson's nephrology business. The company reported $43 million in nephrology revenue in the first quarter, and said INFeD is typically responsible for 25 to 30 percent of that revenue. That implies sales of about $11 million to $13 million per quarter.
